publication date: Jul. 24, 2015
20150724 - Jul. 24, 2015
ISSUE 29 – JULY 24, 2015PDF

MD Anderson No. 1 (Again)

In Rankings by U.S. News & World Report

 

MD Anderson Cancer Center has once again assumed its place at the top of the influential U.S. News & World Report rankings for 2015-2016.
The Houston-based center edged out New York’s Memorial Sloan-Kettering Cancer Center.

As MD Anderson returns to the paramount position it has held 11 times over the past 14 years, it does so despite turmoil between its faculty and administration (The Cancer Letter, July 13).

 

 

FDA & NCI Create Unique Jobs Combining Regulatory Science with Clinical Expertise

NCI and FDA are recruiting three medical oncologists who would divide their time between clinical and regulatory duties—half at the FDA Office of Oncology and Hematology Products, and half at the NCI Center for Cancer Research.

These clinician-scientists would serve as associate directors for clinical research at the OHOP, and as independent, tenure-track principal investigators at the CCR.

    In Brief

    • Charles Roberts named director of St. Jude Comprehensive Cancer Center

    • Eric Rohren named chair of radiology at Baylor College of Medicine

    • Carrie Kitko joins Monroe Carell Jr. Children’s Hospital at Vanderbilt
    • Bruce Quinn joins FaegreBD Consulting

    • Children’s Hospital of Philadelphia opens Buerger Center for Advanced Pediatric Care

    Odomzo Approved in Basal Cell Carcinoma

    FDA approved Odomzo (sonidegib) capsules for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo is marketed by Novartis Pharmaceuticals Corp.

     

    Kyprolis Combination Approved in Relapsed Multiple Myeloma

    FDA approved Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis is sponsored by Onyx Pharmaceuticals Inc., an Amgen subsidiary.

       Drugs and Targets

      • FDA grants orphan drug designation to Anisina in neuroblastoma

      • Amgen submits sNDA for Kyprolis for Injection

      • IriSys awarded five-year contact by NCI

      Copyright (c) 2019 The Cancer Letter Inc.